ID

37384

Description

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2); ODM derived from: https://clinicaltrials.gov/show/NCT02227875

Lien

https://clinicaltrials.gov/show/NCT02227875

Mots-clés

Versions (1)
  1. 21/07/2019 21/07/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

21 juillet 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT02227875

Anglais

Eligibility Type 2 Diabetes NCT02227875

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with an established diagnosis of t2dm per ada 2014 criteria who also fulfill the following:
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
diagnosis established 1 year prior to screening
Description

Disease length

Type de données

boolean

Alias
UMLS CUI [1]
C0872146
insulin-naïve or
Description

Insulin Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0332197
on lantus® once daily at stable dose (±15% variation in dose) for at least 3 months prior to screening
Description

Lantus Dose Stable Once daily

Type de données

boolean

Alias
UMLS CUI [1,1]
C0876064
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0556983
body mass index (bmi) of 18.50 to 40.00 kg/m2 at screening (both values inclusive).
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
stable weight, with no more than 5 kg gain or loss, in the 3 months prior to screening; this information will be collected by patient interview during medical history.
Description

Stable body weight | Weight Gain Amount Timespan | Weight loss Amount Timespan

Type de données

boolean

Alias
UMLS CUI [1]
C0517386
UMLS CUI [2,1]
C0043094
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0872291
UMLS CUI [3,1]
C1262477
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0872291
hemoglobin ≥9.0 g/dl at screening
Description

Hemoglobin measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0518015
glycosylated hemoglobin (hba1c) of <10.5% or between 7.5 to 10.5% for insulin naïve patients at screening.
Description

Hemoglobin A1c measurement | Hemoglobin A1c measurement Insulin Absent

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2,1]
C0474680
UMLS CUI [2,2]
C0021641
UMLS CUI [2,3]
C0332197
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analog preparations used in the trial, or history of significant allergic drug reactions.
Description

Hypersensitivity Ingredient Insulin | Hypersensitivity Ingredient Insulin Analog | Drug Allergy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1550600
UMLS CUI [1,3]
C0021641
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1550600
UMLS CUI [2,3]
C2825028
UMLS CUI [3]
C0013182
history of use of animal insulin within the last 3 years, any insulin other than lantus® within the last 3 months prior to screening, or use of biosimilar insulin glargine at any time prior to screening.
Description

Animal Insulin | Insulin Any | Exception Lantus | Insulin Glargine biosimilar

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003062
UMLS CUI [1,2]
C0021641
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C1552551
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0876064
UMLS CUI [4,1]
C0907402
UMLS CUI [4,2]
C4045974
patients requiring basal-bolus insulin therapy or who in the opinion of the investigator require mealtime insulin in order to achieve glycemic control.
Description

Patient need for Basal insulin Bolus | Mealtime Insulin Glycaemia control

Type de données

boolean

Alias
UMLS CUI [1,1]
C0686904
UMLS CUI [1,2]
C0650607
UMLS CUI [1,3]
C1705509
UMLS CUI [2,1]
C0587119
UMLS CUI [2,2]
C0021641
UMLS CUI [2,3]
C3267174
regular use of immune-modulator therapy in the 1 year prior to screening.
Description

Immunomodulation Regular

Type de données

boolean

Alias
UMLS CUI [1,1]
C1963758
UMLS CUI [1,2]
C0205272
history of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in appendix i) as judged by the investigator.
Description

Episode Quantity Hypoglycemia Severe | Loss of hypoglycemic warning

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332189
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0020615
UMLS CUI [1,4]
C0205082
UMLS CUI [2]
C0342317
history of ≥1 episode of hyperglycemic hyperosmolar coma or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.
Description

Episode Quantity Hyperglycemic Hyperosmolar Coma | Emergency department visit Diabetes mellitus uncontrolled | Hospitalization

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332189
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0020457
UMLS CUI [2,1]
C0586082
UMLS CUI [2,2]
C0421258
UMLS CUI [3]
C0019993
serological evidence of human immunodeficiency virus (hiv), hepatitis b (hbsag) or hepatitis c (hcvab) antibodies at screening.
Description

HIV Seropositivity | Hepatitis B antibody positive | Hepatitis B surface antigen positive | Hepatitis C antibody positive

Type de données

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0860013
UMLS CUI [3]
C0149709
UMLS CUI [4]
C0281863
history of drug or alcohol dependence or abuse during the 1 year prior to screening.
Description

Substance Dependence | Substance Use Disorders

Type de données

boolean

Alias
UMLS CUI [1]
C0038580
UMLS CUI [2]
C0038586
receipt of another investigational drug in the 3 months prior to screening (or as per local regulations), or if the screening visit is within 5 half-lives of another investigational drug (whichever is longer), or scheduled to receive another investigational drug during the current trial period.
Description

Investigational New Drugs | Investigational New Drugs Scheduled

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C0205539
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT02227875

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
patients with an established diagnosis of t2dm per ada 2014 criteria who also fulfill the following:
boolean
C0011860 (UMLS CUI [1])
Disease length
Item
diagnosis established 1 year prior to screening
boolean
C0872146 (UMLS CUI [1])
Insulin Absent
Item
insulin-naïve or
boolean
C0021641 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Lantus Dose Stable Once daily
Item
on lantus® once daily at stable dose (±15% variation in dose) for at least 3 months prior to screening
boolean
C0876064 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0556983 (UMLS CUI [1,4])
Body mass index
Item
body mass index (bmi) of 18.50 to 40.00 kg/m2 at screening (both values inclusive).
boolean
C1305855 (UMLS CUI [1])
Stable body weight | Weight Gain Amount Timespan | Weight loss Amount Timespan
Item
stable weight, with no more than 5 kg gain or loss, in the 3 months prior to screening; this information will be collected by patient interview during medical history.
boolean
C0517386 (UMLS CUI [1])
C0043094 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0872291 (UMLS CUI [2,3])
C1262477 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0872291 (UMLS CUI [3,3])
Hemoglobin measurement
Item
hemoglobin ≥9.0 g/dl at screening
boolean
C0518015 (UMLS CUI [1])
Hemoglobin A1c measurement | Hemoglobin A1c measurement Insulin Absent
Item
glycosylated hemoglobin (hba1c) of <10.5% or between 7.5 to 10.5% for insulin naïve patients at screening.
boolean
C0474680 (UMLS CUI [1])
C0474680 (UMLS CUI [2,1])
C0021641 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Ingredient Insulin | Hypersensitivity Ingredient Insulin Analog | Drug Allergy
Item
history of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analog preparations used in the trial, or history of significant allergic drug reactions.
boolean
C0020517 (UMLS CUI [1,1])
C1550600 (UMLS CUI [1,2])
C0021641 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C1550600 (UMLS CUI [2,2])
C2825028 (UMLS CUI [2,3])
C0013182 (UMLS CUI [3])
Animal Insulin | Insulin Any | Exception Lantus | Insulin Glargine biosimilar
Item
history of use of animal insulin within the last 3 years, any insulin other than lantus® within the last 3 months prior to screening, or use of biosimilar insulin glargine at any time prior to screening.
boolean
C0003062 (UMLS CUI [1,1])
C0021641 (UMLS CUI [1,2])
C0021641 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0876064 (UMLS CUI [3,2])
C0907402 (UMLS CUI [4,1])
C4045974 (UMLS CUI [4,2])
Patient need for Basal insulin Bolus | Mealtime Insulin Glycaemia control
Item
patients requiring basal-bolus insulin therapy or who in the opinion of the investigator require mealtime insulin in order to achieve glycemic control.
boolean
C0686904 (UMLS CUI [1,1])
C0650607 (UMLS CUI [1,2])
C1705509 (UMLS CUI [1,3])
C0587119 (UMLS CUI [2,1])
C0021641 (UMLS CUI [2,2])
C3267174 (UMLS CUI [2,3])
Immunomodulation Regular
Item
regular use of immune-modulator therapy in the 1 year prior to screening.
boolean
C1963758 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
Episode Quantity Hypoglycemia Severe | Loss of hypoglycemic warning
Item
history of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in appendix i) as judged by the investigator.
boolean
C0332189 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0020615 (UMLS CUI [1,3])
C0205082 (UMLS CUI [1,4])
C0342317 (UMLS CUI [2])
Episode Quantity Hyperglycemic Hyperosmolar Coma | Emergency department visit Diabetes mellitus uncontrolled | Hospitalization
Item
history of ≥1 episode of hyperglycemic hyperosmolar coma or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.
boolean
C0332189 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0020457 (UMLS CUI [1,3])
C0586082 (UMLS CUI [2,1])
C0421258 (UMLS CUI [2,2])
C0019993 (UMLS CUI [3])
HIV Seropositivity | Hepatitis B antibody positive | Hepatitis B surface antigen positive | Hepatitis C antibody positive
Item
serological evidence of human immunodeficiency virus (hiv), hepatitis b (hbsag) or hepatitis c (hcvab) antibodies at screening.
boolean
C0019699 (UMLS CUI [1])
C0860013 (UMLS CUI [2])
C0149709 (UMLS CUI [3])
C0281863 (UMLS CUI [4])
Substance Dependence | Substance Use Disorders
Item
history of drug or alcohol dependence or abuse during the 1 year prior to screening.
boolean
C0038580 (UMLS CUI [1])
C0038586 (UMLS CUI [2])
Investigational New Drugs | Investigational New Drugs Scheduled
Item
receipt of another investigational drug in the 3 months prior to screening (or as per local regulations), or if the screening visit is within 5 half-lives of another investigational drug (whichever is longer), or scheduled to receive another investigational drug during the current trial period.
boolean
C0013230 (UMLS CUI [1])
C0013230 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial